January 1, 2019Open Access
View Full PaperAlzheimer's disease drug development pipeline: 2019
Key Points
Key points are not available for this paper at this time.
Abstract
Drug development continues robustly at all phases despite setbacks in several programs in the recent past. Continuing unmet needs require a commitment to growing and accelerating the pipeline.